Drug intelligence / Profile preview

nystatin + triamcinolone

Development stage
Approved
Lead developer
Bristol Myers Squibb
Modality
Small Molecules
Administration
Topical
01

Overview

Nystatin + triamcinolone is a combination topical medication used chiefly to treat cutaneous fungal infections (especially infections caused by Candida species), where symptoms also include significant inflammation or itching[1][2][3][5][6][7][8][9][10]. **Nystatin** is a polyene antifungal that binds to sterols (mainly ergosterol) in fungal cell membranes, thereby altering membrane permeability and resulting in cell death[2][3][7]. **Triamcinolone acetonide** is a synthetic corticosteroid that reduces inflammation, redness, and itching by inhibiting inflammatory mediator pathways, decreasing capillary permeability, and exerting potent antipruritic and vasoconstrictive actions[2][3][7]. The combination is dispensed as a cream or ointment and is applied topically to affected skin areas, usually twice daily for no more than 25 days[1][2][3][5][7][8][9].

Brand names
Mycolog IIMycogen IIMyco-Triacet IIMytrexQuenalogTri-Statin IIN.T.A.
Other names
nystatin and triamcinolone acetonidenystatin/triamcinolonenystatin and triamcinolone
02

Targets

GR (Glucocorticoid receptor)Ergosterol

Beyond the preview

Go deeper on nystatin + triamcinolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on nystatin + triamcinolone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call